Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Approval Plan For COX-2 Inhibitor Includes Lower Doses In Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will experiment with lower doses of its COX-2 inhibitor, 406381, to mitigate the cardiovascular risk seen with the class, CEO Garnier says. While FDA has “blessed” GSK’s Phase III program, testing multiple doses will give GSK “more chances to win.” The agency is also asking for a cardiovascular safety study.
Advertisement

Related Content

FDA's COX-2 Safety Plan: Remove Bextra, Add "Black Box" To Celebrex
COX-2 Pipeline Drugs Will Need Additional Cardiovascular Data, FDA Says
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal

Topics

Advertisement
UsernamePublicRestriction

Register

PS062100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel